J&J MedTech Launches SOUNDSTAR CRYSTAL™ in US, Elevating 2D Intracardiac Imaging Clarity

Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ Ultrasound Catheter in the U.S. to Enhance Cardiac Ablation Procedures May 2025 – Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, has announced the U.S. launch of the SOUNDSTAR CRYSTAL™…

Read MoreJ&J MedTech Launches SOUNDSTAR CRYSTAL™ in US, Elevating 2D Intracardiac Imaging Clarity

Lilly’s Kisunla Approved in Australia for Early Alzheimer’s Treatment

Eli Lilly’s Kisunla Receives Regulatory Approval in Australia for Early Alzheimer’s Treatment Eli Lilly and Company (NYSE: LLY) announced today that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an intravenous infusion therapy administered every four…

Read MoreLilly’s Kisunla Approved in Australia for Early Alzheimer’s Treatment

Aetna Better Health of Illinois Invests $20.4 Million to Improve Health Outcomes Statewide

Aetna Better Health® of Illinois Invests $20.4 Million in Value-Based Care to Improve Health Outcomes in Underserved Communities Aetna Better Health® of Illinois, a CVS Health® company (NYSE: CVS), has distributed $20.4 million in value-based care incentive payments to several…

Read MoreAetna Better Health of Illinois Invests $20.4 Million to Improve Health Outcomes Statewide

AstraZeneca Marks Seventh Consecutive Year of Plenary Data at ASCO, Advancing Breast and Gastric Cancer Care

AstraZeneca Showcases Oncology Breakthroughs at ASCO 2025, Reinforcing Mission to Eliminate Cancer as a Cause of Death AstraZeneca will present new data from over 80 abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 –…

Read MoreAstraZeneca Marks Seventh Consecutive Year of Plenary Data at ASCO, Advancing Breast and Gastric Cancer Care

Cytokinetics Shares New Aficamten Data at ESC Heart Failure 2025 Congress

 Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), and results from a real-world analysis related to…

Read MoreCytokinetics Shares New Aficamten Data at ESC Heart Failure 2025 Congress